Opus Genetics, Inc.
IRD
NASDAQ·Healthcare·Biotechnology·Mkt cap $385.6M
$4.67
▲ +1.52%
P/E
-3.68
Mkt Cap
$385.6M
52-Wk Range
$1.28–$5.81
52-Week Range
$1.28 - $5.81
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 233.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- First-mover advantage in presbyopia treatment development
- Novel small-molecule inhibitor technology (APX3330 platform)
- Diversified clinical pipeline across multiple eye disease categories
- Experienced management team in ophthalmology sector
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Strong growth ahead
FDA Phase III trial progression and potential approvals
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+15.9% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying IRD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 6, 2026
Reported EPS of -$0.14 vs -$0.16 consensus (+10.6% surprise). Revenue of $755.0K vs $2.6M expected (-71.3%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+10.6%
Revenue trend · last 8Q
—
—
+155%
+159%
-20%
-10%
-100%
-74%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$3.9M
$4.3M
$4.4M
$2.9M
$3.1M
$3.9M
$0
$755.0K
Margins · last 8Q
Gross
100.0%
Profit
-1072.6%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: TD Cowen · Jul 29, 2026
vs Industry
How IRD stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related